Barclays Reiterates Overweight Rating on BridgeBio Pharma (BBIO) amid tafamidis IP trial update

March 10, 2026 12:42 PM

Barclays analyst Eliana Merle reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented, "On ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found